NEW YORK, NY / ACCESSWIRE / July 11, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Teva Pharmaceutical Industries Limited ("Teva" or "the Company") (NYSE:TEVA). Investors who purchased Teva securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/teva.
The investigation concerns whether Teva and certain of its officers and/or directors have violated federal securities laws.
On July 11, 2022, the Office of the New York Attorney General (the "OAG") issued a press release entitled "Attorney General James Uncovers Evidence That Teva Pharmaceuticals Lied to Evade Accountability for Opioid Crisis in New York". The press release described a motion by order to show cause filed by the OAG, which "outlines how Teva Pharmaceutical Industries, Ltd. (Teva Parent) made significant and intentional misrepresentations to the Office of the Attorney General (OAG) and the court about its involvement with Teva Pharmaceuticals USA (Teva USA) and role in the opioids industry in the United States in order to evade legal action and accountability. New evidence uncovered by OAG shows that, despite sworn testimony provided to the court that Teva Parent transacted no business in the United States, held no property in the United States, and had no role in its American opioids business, Teva Parent was a primary decision maker for its American subsidiary, maintained property and employees in the country, and exerted control over its finances. In fact, Teva Parent use a complex web of shell corporations to transfer significant funds out of Teva USA and into offshore accounts it owns and control." On this news, the price of Teva's American depositary receipts fell sharply during intraday trading on July 11, 2022.
If you are aware of any facts relating to this investigation or purchasedTeva shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/teva. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC